VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin
Vaccine Information
  • Vaccine Name: Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004432
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Survivin gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector VR expressed novel truncations of survivin, is overexpressed in major types of cancer and is considered an ideal ‘‘universal’’ tumor-associated antigen (Zhang et al., 2012).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000334
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Tumors were significantly inhibited in mice boosted with AD-S8 compared with those in mice given VR-S8/VR- IL2 (P < 0.01). Moreover, complete tumor rejection occurred in 5 of 15 mice, while no tumor rejection was observed in the control group. A Kaplan–Meier plot showed that 53.3% of the mice in the AD-S8- boosted group were alive at 50 days with survival prolonged by 35.6%, whereas only 6.7% of the mice in the VR-S8/VR-IL2 and VR-S8 groups were alive with survival prolonged by 17 and 10.5%, respectively (Zhang et al., 2012).
References
Zhang et al., 2012: Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, Zha X, Yu X, Kong W. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer immunology, immunotherapy : CII. 2012; ; . [PubMed: 22706381].